PMID- 32092224
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20210203
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Linking)
VI  - 22
IP  - 3
DP  - 2020 Jun
TI  - Impact of the patient's body weight on the efficacy and adverse events of 
      valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell 
      transplantation.
PG  - e13270
LID - 10.1111/tid.13270 [doi]
AB  - While the dose of ganciclovir (GCV) is decided base on patients' body weight 
      (BW), that of valganciclovir (VGCV) is fixed as 900 or 1800 mg/d regardless of 
      the patient's BW in preemptive therapy for cytomegalovirus (CMV) reactivation in 
      hematopoietic stem cell transplantation. We analyzed the impact of the patient's 
      BW on the effectiveness and adverse events (AEs) of VGCV. From March 2004 to 
      February 2017, 27 patients received VGCV as a first-line treatment for CMV 
      reactivation. As a historical control group, we extracted 17 patients who started 
      to receive GCV at a similar timing. We used the following definitions of 
      outcomes: speed of reduction of CMV antigenemia (CMV-AG) as a measure of 
      effectiveness, ratios of baseline and minimum value for white blood cell (WBC) 
      and platelet counts, and ratio of baseline and maximum values for serum 
      creatinine (sCr) as measures of AEs. As a result, there was no significant 
      correlation between average daily dose of VGCV with or without adjusting for the 
      patient's BW and speed of reduction of CMV-AG. On the other hand, the decreases 
      in WBC and platelets and the increase in sCr were significantly correlated with 
      the cumulative dose of VGCV. However, the absolute values of the correlation 
      coefficients did not increase when we analyzed the correlations between the 
      BW-adjusted cumulative dose of VGCV and factors associated with adverse events. 
      There were no significant differences in efficacies or AE parameters between the 
      GCV and VGCV groups. In conclusion, the patient's BW did not significantly affect 
      the effectiveness or adverse events of VGCV.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Misaki, Yukiko
AU  - Misaki Y
AUID- ORCID: 0000-0002-4366-315X
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kimura, Shun-Ichi
AU  - Kimura SI
AUID- ORCID: 0000-0001-9827-8526
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kawamura, Masakatsu
AU  - Kawamura M
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kawamura, Shunto
AU  - Kawamura S
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Takeshita, Junko
AU  - Takeshita J
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Yoshino, Nozomu
AU  - Yoshino N
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Yoshimura, Kazuki
AU  - Yoshimura K
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Gomyo, Ayumi
AU  - Gomyo A
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Matsumi, Shimpei
AU  - Matsumi S
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Akahoshi, Yu
AU  - Akahoshi Y
AUID- ORCID: 0000-0001-6825-9340
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Tamaki, Masaharu
AU  - Tamaki M
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kusuda, Machiko
AU  - Kusuda M
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kameda, Kazuaki
AU  - Kameda K
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Wada, Hidenori
AU  - Wada H
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kawamura, Koji
AU  - Kawamura K
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Sato, Miki
AU  - Sato M
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Terasako-Saito, Kiriko
AU  - Terasako-Saito K
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Tanihara, Aki
AU  - Tanihara A
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Nakasone, Hideki
AU  - Nakasone H
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kako, Shinichi
AU  - Kako S
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
FAU - Kanda, Yoshinobu
AU  - Kanda Y
AD  - Division of Hematology, Saitama Medical Center, Jichi Medical University, 
      Saitama-City, Japan.
LA  - eng
GR  - JP17fm0208015/Japan Agency for Medical Research and Development/
PT  - Journal Article
DEP - 20200311
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation 
      Society
JID - 100883688
RN  - 0 (Antiviral Agents)
RN  - GCU97FKN3R (Valganciclovir)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antiviral Agents/*adverse effects/therapeutic use
MH  - *Body Weight
MH  - Cytomegalovirus Infections/*drug therapy/prevention & control
MH  - Female
MH  - Ganciclovir/therapeutic use
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Latent Infection/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Valganciclovir/*adverse effects/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - body weight
OT  - cytomegalovirus
OT  - ganciclovir
OT  - valganciclovir
EDAT- 2020/02/25 06:00
MHDA- 2021/02/04 06:00
CRDT- 2020/02/25 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/01/27 00:00 [revised]
PHST- 2020/02/16 00:00 [accepted]
PHST- 2020/02/25 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2020/02/25 06:00 [entrez]
AID - 10.1111/tid.13270 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2020 Jun;22(3):e13270. doi: 10.1111/tid.13270. Epub 2020 Mar 
      11.